Antoni Ribas, MD, PhD is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA.

His NCI, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award and a National Cancer Institute (NCI) Outstanding Investigator Award.